To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Status:
Completed
Trial end date:
2019-06-04
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to investigate the safety and tolerability of
TAEST16001（TCR Affinity Enhancing Specific T cell Therapy）in the multi-line treatment failed
advanced solid tumors except non small cell lung cancer,including liver cancer,gastric
cancer,esophageal cancer,bone and soft tissue tumors,breast cancer, bladder
carcinoma,prostate carcinoma,thyroid cancer, ovarian cancer and so on. The patients must meet
the two criteria: human leukocyte antigens (HLA)-A*0201+ and NY-ESO-1 positive cells≥25% by
immunohistochemistry.
Phase:
Phase 1
Details
Lead Sponsor:
Zhujiang Hospital
Collaborators:
Guangdong Xiangxue Precision Medical Technology Co., Ltd. Guangzhou Xiangxue Pharmaceutical Co., Ltd Xiangxue Life Science Research Center Xiangxue Pharmaceutical